A Phase 2, Randomized, Open-Label Study of Lucitanib in Patients with Fgf Aberrant Metastatic Breast Cancer.
Journal of Clinical Oncology（2015）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined